Publications by authors named "S J Molica"
Chronic Lymphocytic Leukemia Care and Beyond: Navigating the Needs of Long-Term Survivors.
Cancers (Basel)
January 2025
Chronic lymphocytic leukemia (CLL) treatment has undergone a significant evolution with a shift from historical chemotherapeutic regimens to targeted therapies such as Bruton tyrosine kinase (BTK) and BCL-2 inhibitors. These advancements have been associated with a notable improvement in survival rates with a transformation of CLL into a chronic and manageable condition for most persons with this disease. However, as a consequence of improved outcomes, long-term CLL survivors now face emergent challenges which include a risk of infections, cardiovascular complications, and secondary malignancies.
View Article and Find Full Text PDFArticle Synopsis
- The occurrence of both chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) in a single patient is very uncommon, and there are only a handful of documented cases.
- The case described involves a patient with CML who successfully responded to treatment with imatinib, achieving a major molecular response.
- Later, the same patient developed CLL, which required the addition of ibrutinib to their treatment regimen.